Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
about
How cell death shapes cancerCancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueThe role of aberrant proteolysis in lymphomagenesisDinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.Characterization of miR-122-independent propagation of HCV.Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivoBIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1The BCL-2 protein family, BH3-mimetics and cancer therapy.Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBxCritical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.Mitochondrial DNA plasticity is an essential inducer of tumorigenesis.Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Epstein-Barr virus and Burkitt lymphoma.Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.Survival control of malignant lymphocytes by anti-apoptotic MCL-1.Impact of conditional deletion of the pro-apoptotic BCL-2 family member BIM in miceAnti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis.Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability.The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain.BCL-W has a fundamental role in B cell survival and lymphomagenesis.Close encounter of the covalent kind: Inhibiting MCL1's proapoptotic activity with covalent inhibitors.CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.Why do BCL-2 inhibitors work and where should we use them in the clinic?The BCL-2 arbiters of apoptosis and their growing role as cancer targets.MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation.Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.
P2860
Q27021441-4CA6C538-9EC1-4C50-BFEC-B66C1615A600Q28066868-72A0B803-9B3E-4F1B-8524-4D1F5B385275Q28084404-BB44144E-A502-4E7D-8D3C-96E8E1E0CD6CQ30843418-B497CF50-4260-41F2-8913-7FE25ED47925Q33719172-2D2F534A-AA83-4299-A6C8-BF9B6C1D4066Q34070349-1992327F-DFEE-43BA-AFAC-4E1D5F400460Q35101648-E3389B0F-4197-4C71-A724-834AD8055DF1Q35236066-FC7AF908-030D-442D-B576-8965E18A011BQ35543223-F07D17E0-6283-4FE2-9594-B05FFDD98E09Q35634881-029C0898-87E8-4D6F-8719-57B1D63D11FDQ35920657-12A1B243-6D7E-4406-8143-59BD2292DBACQ36067778-BAEE2AFE-8B93-422A-9DDE-056A1EC99BD5Q36694117-A32DB1E1-2276-4CFB-BB46-8103DBC6BB5AQ36774970-B3AAFC46-6078-4D88-A816-CEEC776CB20AQ36812163-D0505E03-C24F-4CD3-B511-7B076E575DEFQ37164396-E062ABF6-B023-4082-9EB3-54D17DC268EAQ37452081-46347206-C63A-41D1-B95C-28E599EEECB3Q38193997-6F47F137-51F8-471B-8CC7-33F1154BFD86Q38270680-771CD253-5B48-48AF-8427-55CED514103BQ38307680-E3794368-1A96-444E-9817-8B543794584FQ38563530-17EEABD8-6D1F-4A37-8B3C-51D258D3009BQ38742807-5D53EB47-B6E2-4001-90CD-E1FC50505A60Q38779981-693A4901-B8D6-4A96-A57C-437816C660DEQ38914858-70FEB355-6A1D-4E2D-A222-50AFA3EC2AFDQ39116343-4BAC565D-27D5-427D-86AB-F5660E9877DCQ39477734-3472AA8E-B688-4CAD-8444-13E313034D52Q40812418-4DDD3D72-5133-44D8-AE1B-3F39EB026BACQ41836292-330B562E-A2FC-4BC3-8299-C35AA7877A65Q42016261-6E5AF2B1-CC59-449C-98ED-175865D91A87Q42177793-F562D51A-DB5D-4368-ABA2-13070B34F1C5Q42328732-45C67329-E9C8-40BA-AB18-E15C7749981DQ42335354-081ADEB9-FC7A-4DC0-B016-D8A470149FDDQ42693009-98751CE6-DBE4-448B-A26C-5CF980C40348Q47159040-CC22D347-D111-48D0-B200-E859A88C82BCQ47166330-BEBF9615-EA8E-4F1C-B16A-18670B018728Q47215137-B7F0AAC1-E3EE-446C-AEA5-8B18459BC59BQ47368952-324C7E14-35FF-407D-B684-57BE47D950CBQ47550209-A00E5CEA-CC85-4A52-B961-5B87EA995111Q47564485-887FC95A-4584-4565-A940-CA1DDEE6F9CBQ47571040-131B47BE-9751-45F1-8684-C0FAFF298779
P2860
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting of MCL-1 kills MYC-d ...... hen they bear mutations in p53
@en
Targeting of MCL-1 kills MYC-d ...... en they bear mutations in p53.
@nl
type
label
Targeting of MCL-1 kills MYC-d ...... hen they bear mutations in p53
@en
Targeting of MCL-1 kills MYC-d ...... en they bear mutations in p53.
@nl
prefLabel
Targeting of MCL-1 kills MYC-d ...... hen they bear mutations in p53
@en
Targeting of MCL-1 kills MYC-d ...... en they bear mutations in p53.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting of MCL-1 kills MYC-d ...... hen they bear mutations in p53
@en
P2093
Alan B Rickinson
Gemma L Kelly
Mikara Robati
Stefan P Glaser
Stephanie Grabow
Toru Okamoto
P2860
P356
10.1101/GAD.232009.113
P50
P577
2014-01-01T00:00:00Z